Lexington, KY – Carina Medical LLC announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for INTDose. INTDose is a Monte Carlo (MC)-based software for independent dose verification in radiotherapy treatment planning. Monte Carlo simulation is regarded as the gold standard for estimating the amount of energy deposited into a medium by ionizing radiation; however, the clinical utility of using MC simulations for independent dose calculations is often hindered by the computational resources and time required to run these simulations. INTDose provides a solution to these bottlenecks by utilizing virtual source models and parallel processing to provide a high speed and accurate validation of treatment plans for delivery methods including TomoTherapy, conventional Varian Linac IMRT, VMAT, and Varian Halcyon. The product also includes a user-friendly private-cloud-based interface, a fully automated workflow, and scripting compatibility with Varian's Eclipse treatment planning system (TPS) to allow for the incorporation into clinical workflows with high customizability.Continue reading
INTDose's MC algorithms compute 3D doses based on treatment plans and patient imaging and summarize the results in a dynamic report. The report includes comparisons between TPS and MC doses at the global scale, as well as stratified by treatment volumes and organs at risk. Reports also include a gamma index analysis, dose volume histograms, and the ability to scroll through image slices overlaid with TPS doses, MC doses, and gamma index maps. Users have the option to view reports in a web-based interface, or automatically exported to a local file for future review.
Independent verification of the dose to a patient has been a mainstay of radiation oncology quality assurance (QA). Traditionally, methods for independent MU and dose verification were single point calculations in the target (1D). With the advent of treatment techniques like IMRT, which introduces non-uniform dose distributions, dosimetric agreement of the treatment volume and organs at risk are often of interest. AAPM TG-219 recommends that "2D/3D verification for IMRT and VMAT is recommended. Vendors should move away from systems that offer only a single comparison point and should develop secondary dose/MU verification systems that compute the dose distribution throughout the high dose volume."
Xue Feng, Ph.D, CEO of Carina Medical said, “We are excited to be able to make this product available to assist with this pillar of radiotherapy QA. Now, with FDA approval for two of our products, we stand to make an even greater impact in improving the radiotherapy treatment planning process. I’m grateful for our team’s hard work in helping to achieve this milestone.” The Company’s commercialization in the U.S. focuses on the use of cutting-edge AI technology to solve one of the most time-consuming tasks in radiation treatment planning, and therefore enable a more efficient workflow for radiation therapy and lead to improved cancer treatments. For more information on Carina Medical, please click here, or visit us at the AAPM annual meeting, Start-up Space, booth 16. Our efforts in the development of virtual source models will also be presented as part of the annual meeting's scientific program.
Lexington, KY – Carina Medical LLC announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for INTContour. INTContour is an AI-based automatic contouring software that covers more than 60 organs from all anatomical body parts. Based on award-winning algorithms, the segmentation performance is independently validated in multiple academic institutions with high accuracy and robustness. The product also includes a user-friendly private-cloud-based interface that is designed to fit into clinical workflows with high customizability.Continue reading
Xue Feng PhD, CEO of Carina Medical said, “We are beyond excited with the news of INTContour’s FDA clearance. This represents the culmination of our team’s hard work to create our vision of the ideal product to support and streamline the radiotherapy treatment planning process.” The Company’s commercialization in the U.S. focuses on the use of cutting-edge AI technology to solve one of the most time-consuming tasks in radiation treatment planning, and therefore enable a more efficient workflow for radiation therapy and lead to improved cancer treatments. For more information on Carina Medical, please click here.
Lexington, KY -- Carina Medical has received a $2M award from the National Cancer Institute to continue the development of AI based auto-segmentation software for radiation therapy treatment planning.
Carina Medical will continue to develop novel solutions for more efficient radiation treatment planning. It will support both CT- and MRI-based organ segmentation and site-specific segmentation models to increase the robustness of the AI system.
Carina Medical is in collaboration with the University of Kentucky and the University of California, Davis to develop and validate the auto-segmentation product.
Frankfort, KY -- The Cabinet for Economic Development KY Innovation awarded Carina Medical $150K SBIR/STTR Matching Funds.
“SBIR/STTR funds are a vital component in launching and growing innovative, high-tech companies here in Kentucky,” said Gov. Matt Bevin. “The commonwealth’s matching program is one of the strongest in the nation, enabling us to support early-stage companies with cutting-edge technologies. This year’s recipients are a testament to the outstanding work being done in our state across many disciplines. We look forward to watching them flourish right here in America’s engineering and manufacturing center of excellence.”
This grand challenge is held in multiple phases. Phase 1 was completed before the 2019 AAPM annual meeting when teams applied their algorithms to segment 12 test images and upload their results for the challenge organizers to evaluate. Phase 2 was conducted live at the AAPM annual meeting when teams were provided with 10 new test images to segment. In both phases, the Carina Medical team edged out the Varian team to win the 1st place.
The analysis performed by the challenge organizers has showed that the contouring accuracy of Carina Medical’s algorithm has surpassed that of human experts’ manual contouring. This is further proof of the superiority of Carina Medical’s AI technology. Creating faster and more accurate segmentation algorithms will not only reduce the health care cost and provide a better treatment plan, but also make advanced treatment techniques such as adaptive radiation therapy more practical.
Lexington, KY –- Carina Medical has received a $300,000 Phase I SBIR award from the National Institute of Health to develop AI assisted auto-segmentation software for radiation therapy treatment planning.Continue reading
More than 60 percent of cancer patients will encounter radiation therapy during their
course of treatment. In radiation treatment, both tumor and healthy organs have to be accurately contoured so
that radiation oncology teams can produce plans that deliver enough dose to the tumor while sparing healthy
organs. In current clinical practice, the main method of segmenting OARs is through manual contouring, which
can be both time-consuming and inaccurate. A fast and accurate contouring software can not only reduce
health care costs and provide a better treatment plan, but also advances the adoption of adaptive radiation
therapy, which was previously bottlenecked by the contouring process.
Carina Medical will work with the University of Kentucky to develop and validate the auto-segmentation product.